Cargando…
Salvage of Side Branch by Provisional “TAP Technique” Using Absorb™ Bioresorbable Vascular Scaffolds for Bifurcation Lesions: First Case Reports with Technical Considerations
Recent technological developments have led to the development of Absorb™ bioresorbable vascular scaffold (BVS) [Abbott Vascular, Santa Clara, USA] for percutaneous treatment of coronary artery disease by percutaneous coronary intervention (PCI). The BVS is now approved for use in many countries but...
Autores principales: | Seth, Ashok, Sengottuvelu, G, Ravisekar, V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489321/ https://www.ncbi.nlm.nih.gov/pubmed/24677764 http://dx.doi.org/10.1002/ccd.25444 |
Ejemplares similares
-
Bioresorbable magnesium scaffold in the treatment of simple coronary bifurcation lesions: The BIFSORB pilot II study
por: Barkholt, Trine Ø., et al.
Publicado: (2021) -
Three‐year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus‐eluting stent in routine PCI in patients with diabetes mellitus—AIDA sub‐study
por: Kerkmeijer, Laura S.M., et al.
Publicado: (2020) -
Mechanical properties of the drug‐eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug‐eluting stent
por: Barkholt, Trine Ø., et al.
Publicado: (2019) -
Serial invasive imaging follow‐up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold
por: Tovar Forero, Maria Natalia, et al.
Publicado: (2019) -
Bioresorbable vascular scaffolds versus conventional drug-eluting stents across time: a meta-analysis of randomised controlled trials
por: Jackson-Smith, Elliot, et al.
Publicado: (2022)